Knee osteoarthritis
Conditions
Interventions
A group of 50 patients undergoing primary unilateral total knee arthroplasty (TKA) between September 2025 and October 2026, who will receive postoperative tranexamic acid administration.
A control gro
Sponsors
Takagi Hospital Oume Knee Surgery Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients will receive tranexamic acid for 14 days postoperatively, administered at 1000 mg twice daily. On the day of surgery and the following day, the drug will be given intravenously; thereafter, for the subsequent 12 days, it will be administered orally. For patients with an eGFR between 30 and 60, tranexamic acid will be given at 500 mg twice daily. For patients with an eGFR > 60, the dosage will be 1000 mg twice daily.
Exclusion criteria
Exclusion criteria: Patients with an estimated glomerular filtration rate (eGFR) below 30.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee circumference measurements were performed preoperatively and on postoperative days 1, 3, 7, 14, and 21. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain Visual Analog Scale (VAS) scores on postoperative days 7, 14, and 21 Knee range of motion (ROM) Hemoglobin reduction rate | — |
Countries
Japan
Contacts
Public ContactYoshinori Mikashima
Takagi Hospital Oume Knee Surgery Center
Outcome results
None listed